Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens

References

• Jain P, Fayad LE, Rosenwald A, et al. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol. 2013;88(9):798–802. doi:10.1002/ajh.2346723695956
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(3):815–821. doi:10.1182/blood.V99.3.81511806981
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Tolga Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci. 2008;105(36):13520–13525. doi:10.1073/pnas.080429510518765795
   PubMed Web of Science ®Google Scholar
• Vose JM. Relapsed diffuse large B-cell lymphoma: clinical utility of cell of origin. J Clin Oncol. 2011;29(31):4065–4066. doi:10.1200/JCO.2011.37.573321947831
   PubMed Web of Science ®Google Scholar
• Martelli M, Ferreri AJ, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146–171. doi:10.1016/j.critrevonc.2012.12.00923375551
   PubMed Web of Science ®Google Scholar
• Smith A, Howell D, Crouch S, et al. Cohort profile: the Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. Int J Epidemiol. 2018;47(3):700. doi:10.1093/ije/dyx190
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-64356926980727
   PubMed Web of Science ®Google Scholar
• Gang AO, Strř C, Pedersen M, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol. 2012;23:147–153. doi:10.1093/annonc/mdr05821460380
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–2693. doi:10.1182/blood.v99.8.268511929754
   PubMed Web of Science ®Google Scholar
• Garcia-Suarez J, Banas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007;136(2):276–285. doi:10.1111/j.1365-2141.2006.06438.x17233819
   PubMed Web of Science ®Google Scholar
• Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170:504–514. doi:10.1111/bjh.1346325907897
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195–1202. doi:10.3324/haematol.1281018556402
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Tamaru JI, et al. Clinocopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21:2069–2074. doi:10.1093/annonc/mdq05720231297
   PubMed Web of Science ®Google Scholar
• Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29–36. doi:10.1182/blood-2007-01-04187117360935
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32. doi:10.1182/blood-2014-07-59104025499448
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. doi:10.1038/3500050110676951
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Suzuki R, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601–1607. doi:10.1093/annonc/mdq62721199885
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohno T, Oka K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol. 1999;105(4):1133–1139. doi:10.1046/j.1365-2141.1999.01513.x10554834
   PubMed Web of Science ®Google Scholar
• Hyo R, Tomita N, Takeuchi K, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol. 2010;28(1):27–32. doi:10.1002/hon.89619358143
   PubMed Web of Science ®Google Scholar
• Westin J, McLaughlin P. De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. Leuk Lymphoma. 2010;51(1):161–163. doi:10.3109/1042819090332424419863175
   PubMed Web of Science ®Google Scholar
• Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758–765. doi:10.3324/haematol.2011.05653122133772
   PubMed Web of Science ®Google Scholar
• Garcia-Suarez J, Flores E, Callejas M, et al. Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma. Br J Haematol. 2013;160(4):510–514. doi:10.1111/bjh.1214423228045
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-154514504078
   PubMed Web of Science ®Google Scholar
• Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103–2113. doi:10.1038/leu.2012.8322437443
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214. doi:10.1002/(ISSN)1097-01427459811
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol. 1999;17(4):1244. doi:10.1200/JCO.1999.17.4.124410561185
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi:10.1200/JCO.2006.09.240317242396
   PubMed Web of Science ®Google Scholar
• Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter’s syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol. 1995;147(1):207–216.7541611
   PubMed Web of Science ®Google Scholar
• Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13(9):1441–1447.10482997
   PubMed Web of Science ®Google Scholar
• Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–2263. doi:10.1182/blood-2012-06-43584223335369
   PubMed Web of Science ®Google Scholar
• Aukema SM, Kreuz M, Kohler CW, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–735. doi:10.3324/haematol.2013.09182724179151
   PubMed Web of Science ®Google Scholar
• Li S, Weiss VL, Wang XJ, et al. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis. Am J Surg Pathol. 2016;40(2):253–261. doi:10.1097/PAS.000000000000054226448193
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–3467. doi:10.1200/JCO.2011.41.434222665537
   PubMed Web of Science ®Google Scholar
• Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2008;19(11):1921–1926.
   PubMed Web of Science ®Google Scholar
• Thakral B, Edeiros LJ, Desai P, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98(4):415–421. doi:10.1111/ejh.1284728039906
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190. doi:10.1200/JCO.2010.28.161820660832
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive Non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–1690. doi:10.1056/NEJMoa130107724171516
   PubMed Web of Science ®Google Scholar
• Alinari L, Gru A, Quinion C, et al. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multi-center, rituximab treated cohort. Am J Hematol. 2016;91(4):395–399. doi:10.1002/ajh.2429926800311
   PubMed Web of Science ®Google Scholar